PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES

NCT02086656 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Liver Metastases

Interventions

DRUG: capecitabine, oxaliplatin, irinotecan and bevacizumab

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano